PPBT stock forecast, quote, news & analysis
Purple Biotech Ltd is a clinical-stage biotechnology company focused on the development and commercialization of pharmaceuticals... Show more
Why Purple Biotech (PPBT) Stock Is Down 25% in the Last 30 Days
Key Takeaways
- Purple Biotech (PPBT) shares have declined roughly 25% over the last 30 days, falling from about $1.44 to near $1.08–$1.09.
- The pullback largely reflects profit-taking after a sharp early-September rally tied to a U.S. patent allowance for its CAPTN-3 platform.
- Concerns over a limited cash runway, potential future dilution, and an ongoing CEO transition have weighed on investor sentiment.
- Purple Biotech remains a clinical-stage, pre-revenue oncology developer with no approved products and a pipeline spanning Phase 2 and preclinical assets.
- The company regained Nasdaq minimum-bid-price compliance following a 2026 ADS ratio change, but the stock has since drifted back toward the $1 threshold.
Purple Biotech (PPBT) Company Overview and Market Position
Purple Biotech Ltd. is a clinical-stage biotechnology company headquartered in Rehovot, Israel, focused on developing therapies designed to overcome tumor immune evasion and drug resistance in cancer patients. Its pipeline includes CM24, a humanized monoclonal antibody being evaluated in a Phase 2 trial for pancreatic ductal adenocarcinoma in combination with anti-PD-1 checkpoint inhibitors, and NT219, a small-molecule inhibitor of IRS1/2 and STAT3 in Phase 2 development for recurrent or metastatic head and neck squamous cell carcinoma and colorectal adenocarcinoma.
The company's flagship platform is CAPTN-3, a conditionally activated tri-specific antibody technology with lead preclinical candidates IM1240 and IM1305. Purple Biotech has a collaboration agreement with Bristol Myers Squibb to evaluate CM24 alongside nivolumab. As a pre-revenue developer, the company relies on equity financing to fund operations, which makes its stock sensitive to both clinical catalysts and capital-raising news.
Purple Biotech (PPBT) Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, PPBT has fallen roughly 25%, declining from approximately $1.44 to about $1.08–$1.09. The move has been a steady drift lower rather than a single-day shock, with the stock erasing most of the gains generated by an early-September surge.
The quarterly picture tells a similar story. From a mid-July level near $1.45, the stock spiked dramatically in early September before retracing. The company's announcement of a U.S. Patent and Trademark Office notice of allowance for its tri-specific antibody platform sent shares sharply higher on unusually heavy volume, but those gains proved short-lived. By late October, the stock had given back the rally and ended the period down approximately 25% from its mid-July starting point.
What Drove PPBT Stock Price in the Last 30 Days
The most significant factor behind the recent decline has been the unwinding of a sharp, catalyst-driven rally. In early September, news of a U.S. patent allowance covering tri-specific antibody constructs and methods triggered a surge in trading volume and a notable intraday spike in the share price. As the enthusiasm faded, the stock began a prolonged pullback, with investors taking profits and repositioning.
Several fundamentals have reinforced the downtrend. Purple Biotech is pre-revenue and reported a net loss for its latest fiscal year, including a significant non-cash impairment charge related to in-process research and development assets for CM24 and NT219. The company's cash position remains modest relative to its development ambitions, and management has indicated it will need to raise substantial additional capital to advance its pipeline. A previously disclosed $200 million mixed securities shelf filing has kept dilution concerns in focus.
The leadership transition has also contributed to uncertainty. The company's chief executive officer stepped down from the role in August 2026, with a search for a successor underway. Combined with a lack of near-term clinical data readouts, these factors have left the stock vulnerable to selling pressure in a challenging environment for small-cap biotechnology names.
What Drove PPBT Stock Performance Over the Last Quarter
Over the full quarter, Purple Biotech's stock experienced a sharp rally followed by a full retracement. The primary catalyst was the September patent allowance announcement for the CAPTN-3 platform, which briefly lifted the shares to levels well above their mid-summer trading range. Supporting sentiment were new preclinical data on the IM1240 tri-specific antibody presented at the European Association for Cancer Research annual congress and a collaboration with Converge Bio aimed at applying generative AI to accelerate the company's antibody platform.
However, the broader narrative has been dominated by execution and funding risks. The company regained Nasdaq minimum-bid-price compliance earlier in 2026 through a change in its ADS ratio, effectively a reverse split, but the stock has since declined back toward the $1 level. Analyst coverage has remained cautious; H.C. Wainwright lowered its price target while maintaining a Buy rating, citing the company's low cash position. Together, these developments created a volatile quarter in which the stock ultimately ended lower despite a powerful mid-period spike.
Trending AI Robots
Tickeron's Trending AI Robots page curates a selection of AI-driven trading bots that are currently generating standout performance. While Tickeron offers hundreds of automated bots trading thousands of tickers, only the top-performing and most relevant strategies are surfaced in this section, helping traders filter through a large and diverse pool. Each bot differs in strategy, timeframe, and performance metrics, so investors can compare approaches that range from short-term momentum to longer-horizon signals. For those interested in systematic, data-driven market analysis, exploring the Trending AI Robots section can provide additional perspective on how algorithmic tools are monitoring evolving market conditions.
PPBT Stock Forecast Drivers: What Investors Should Watch Next
Investors following Purple Biotech should monitor several key factors in the periods ahead. The most immediate is the company's cash runway and any financing activity, given its limited balance sheet and pre-revenue status. Capital raises, whether through the existing shelf or new offerings, could influence the share count and near-term sentiment.
Clinical and regulatory milestones remain central to the long-term story. The company has indicated plans to advance IM1240 toward an Investigational New Drug application, a step that could refocus attention on the CAPTN-3 platform. Updates on CM24 partnering or investment and progress in the investigator-initiated NT219 study are also worth watching. Finally, the appointment of a new chief executive officer and broader conditions in the small-cap biotechnology sector may shape the stock's trajectory, along with any renewed Nasdaq listing-compliance considerations.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
PPBT in downward trend: price dove below 50-day moving average on September 16, 2026
PPBT moved below its 50-day moving average on September 16, 2026 date and that indicates a change from an upward trend to a downward trend. In 36 of 37 similar past instances, the stock price decreased further within the following month. The odds of a continued downward trend are 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 07, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on PPBT as a result. In 73 of 82 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 89%.
The 10-day moving average for PPBT crossed bearishly below the 50-day moving average on September 24, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 13 of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PPBT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.
The Aroon Indicator for PPBT entered a downward trend on October 21, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where PPBT's RSI Indicator exited the oversold zone, 43 of 53 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 81%.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 9 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +6.48% 3-day Advance, the price is estimated to grow further. Considering data from situations where PPBT advanced for three days, in 168 of 225 cases, the price rose further within the following month. The odds of a continued upward trend are 75%.
PPBT may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 55 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.152) is normal, around the industry mean (2.988). P/E Ratio (-0.024) is within average values for comparable stocks, (-1.158). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (123.903) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (438.009).
The Tickeron Price Growth Rating for this company is 89 (best 1 - 100 worst), indicating slightly worse than average price growth. PPBT’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PPBT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a provider of pharmaceutical drug discovery and development services
Industry Biotechnology